Is NRXP or NVCT more undervalued in 2026?

CirclFi compares NRX Pharmaceuticals, Inc. (NRXP) and Nuvectis Pharma, Inc. (NVCT) using 13 institutional-grade valuation models. NRXP has a Quality of Company score of 3.9/10 while NVCT scores 3.8/10.

Which is a better buy — NRXP or NVCT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NRXP and NVCT valuations compare?

NRXP at $4.42 and NVCT at $9.75 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NRXP vs NVCT Valuation Comparison 2026 — Intrinsic Value Analysis

NRXP

Pharmaceutical Preparations

NRX Pharmaceuticals, Inc.

Quality

3.9

out of 10

Value Trap

LOW

Price

$4.42

Last close

Models

10/13

Active

NVCT

Pharmaceutical Preparations

Nuvectis Pharma, Inc.

Quality

3.8

out of 10

Value Trap

SAFE

Price

$9.75

Last close

Models

6/13

Active

Model-by-Model Comparison

Model	Type	NRXP Fair Value	NRXP Upside	NVCT Fair Value	NVCT Upside
Bayesian DCF	Intrinsic	$0.86	-80.5%	$3.41	-65.0%
Earnings Power Value	Intrinsic	$0.34	-89.0%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	—	—	$1.15	-88.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NRXP vs NVCT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NRXP vs NVCT — Which Stock Is More Undervalued?

NRXP scores higher with a 3.9/10 quality rating vs NVCT's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NRX Pharmaceuticals, Inc. (NRXP) and Nuvectis Pharma, Inc. (NVCT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NRXP currently trades at $4.42 with a QOC of 3.9/10, while NVCT trades at $9.75 with a QOC of 3.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).